9 studies found for:    MK-4305
Show Display Options
Rank Status Study
1 Completed A Study to Evaluate Next Day Effects of MK-4305 on Driving Performance (MK-4305-035 AM1)
Condition: Insomnia
Interventions: Drug: MK-4305 40 mg;   Drug: MK-4305 20 mg;   Drug: Zopiclone;   Drug: Grossly Matching Placebo for Zopiclone;   Drug: Matching Placebo for MK-4305
2 Completed
Has Results
Safety and Efficacy Study of Suvorexant in Participants With Primary Insomnia - Study B (MK-4305-029)
Condition: Primary Insomnia
Interventions: Drug: Suvorexant High Dose (HD);   Drug: Suvorexant Low Dose (LD);   Drug: Comparator: Placebo
3 Completed
Has Results
Safety and Efficacy Study of Suvorexant in Participants With Primary Insomnia - Study A (MK-4305-028)
Condition: Primary Insomnia
Interventions: Drug: Suvorexant High Dose (HD);   Drug: Suvorexant Low Dose (LD);   Drug: Comparator: Placebo
4 Completed
Has Results
Effects of Suvorexant in Participants With Obstructive Sleep Apnea (MK-4305-036 AM1)
Condition: Sleep Apnea
Interventions: Drug: Suvorexant;   Drug: Matching Placebo
5 Completed
Has Results
Pharmacokinetics of Suvorexant in Participants With Hepatic Insufficiency (MK-4305-017)
Conditions: Insomnia;   Hepatic Insufficiency
Intervention: Drug: Suvorexant
6 Completed
Has Results
Effects of Suvorexant in Patients With Chronic Obstructive Pulmonary Disease (MK-4305-032 AM3)
Condition: Insomnia
Interventions: Drug: suvorexant;   Drug: Placebo
7 Completed
Has Results
Pharmacokinetics of Suvorexant in Participants With Impaired Renal Function (MK-4305-023)(COMPLETED)
Condition: Insomnia
Intervention: Drug: Suvorexant
8 Completed Phase IIB 2-Period Crossover Polysomnography Study in Participants With Primary Insomnia (MK-4305-006)
Condition: Primary Insomnia
Interventions: Drug: Suvorexant;   Drug: Dose-matched Placebo to Suvorexant
9 Completed
Has Results
A Long Term Safety Study of Suvorexant in Participants With Primary Insomnia (MK-4305-009 AM3)
Condition: Insomnia
Interventions: Drug: Suvorexant;   Drug: Dose-matched Placebo to Suvorexant

Indicates status has not been verified in more than two years